Skip to main content
Premium Trial:

Request an Annual Quote

Nuclea, Clark University to Start Proteomics, Metabolomics Center

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Diagnostics developer Nuclea Biotechnologies and Clark University will establish a new center to use proteomics and metabolomics methods in conducting biomarker research focused on cancer, Nuclea said yesterday.

The Pittsfield, Mass.-based firm will expand an ongoing partnership with Clark to establish a new Proteomic and Metabolomic Center on the university's campus in Worcester.

The center will bring together tools for sample preparation and mass spectrometry with Clark's established nuclear magnetic resonance imaging resource.

The large volumes of data generated from Nuclea's clinical repository and from scientific samples will be analyzed through a newly established computer cluster network at Clark and Nuclea's database.

Nuclea is focused on developing gene, protein, and antibody biomarkers and pharmacogenetic diagnostic assays that can predict which treatments will be effective for certain patients.

"The research being conducted at Clark, using the state-of-the-art equipment and technology, will lead to new biomarkers that will help doctors identify deadly cancers in hard-to-diagnose patients and prescribe the most effective treatments," Nuclea CEO and President Patrick Muraca said in a statement.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.